114 related articles for article (PubMed ID: 3553435)
1. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.
Keating MJ; Gehan EA; Smith TL; Estey EH; Walters RS; Kantarjian HM; McCredie KB; Freireich EJ
J Clin Oncol; 1987 May; 5(5):710-21. PubMed ID: 3553435
[TBL] [Abstract][Full Text] [Related]
2. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
[TBL] [Abstract][Full Text] [Related]
3. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
[TBL] [Abstract][Full Text] [Related]
4. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
[TBL] [Abstract][Full Text] [Related]
5. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia.
Keating MJ; Scouros M; Murphy S; Kantarjian H; Hester J; McCredie KB; Hersh EM; Freireich EJ
Leukemia; 1988 Mar; 2(3):157-64. PubMed ID: 3347094
[TBL] [Abstract][Full Text] [Related]
6. Intensive treatment of acute leukemia in adults 70 years of age and older.
Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
8. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.
Kalwinsky D; Mirro J; Schell M; Behm F; Mason C; Dahl GV
J Clin Oncol; 1988 Jul; 6(7):1134-43. PubMed ID: 3292713
[TBL] [Abstract][Full Text] [Related]
9. Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
Spinolo JA; Dicke KA; Horwitz LJ; Jagannath S; Zander AR; Auber ML; Spitzer G
Bone Marrow Transplant; 1990 Feb; 5(2):111-8. PubMed ID: 1690035
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
11. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
13. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
14. Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and levamisole maintenance.
Morrison FS; Kopecky KJ; Head DR; Athens JW; Balcerzak SP; Gumbart C; Dabich L; Costanzi JJ; Coltman CA; Saiki JH
Leukemia; 1992 Jul; 6(7):708-14. PubMed ID: 1625490
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
Fenaux P; Tertian G; Castaigne S; Tilly H; Leverger G; Guy H; Bordessoule D; Leblay R; Le Gall E; Colombat P
J Clin Oncol; 1991 Sep; 9(9):1556-61. PubMed ID: 1805818
[TBL] [Abstract][Full Text] [Related]
16. Treatment-subgroup interaction: an example from a published, phase II clinical trial.
Behrendt CE; Gehan EA
Contemp Clin Trials; 2009 May; 30(3):279-81. PubMed ID: 19232549
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin.
Coltman CA; Bodey GP; Hewlett JS; Haut A; Bickers J; Balcerzak SP; Costanzi JJ; Freireich EJ; McCredie KB; Groppe C; Smith TL; Gehan EA
Arch Intern Med; 1978 Sep; 138(9):1342-8. PubMed ID: 686922
[TBL] [Abstract][Full Text] [Related]
18. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Kantarjian HM; Walters RS; Keating MJ; Smith TL; O'Brien S; Estey EH; Huh YO; Spinolo J; Dicke K; Barlogie B
J Clin Oncol; 1990 Jun; 8(6):994-1004. PubMed ID: 2189958
[TBL] [Abstract][Full Text] [Related]
19. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
20. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
